These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33324841)

  • 1. Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved
    Adeagbo BA; Akinlalu AO; Phan T; Guderian J; Boukes G; Willenburg E; Fenner C; Bolaji OO; Fox CB
    ACS Omega; 2020 Dec; 5(48):31306-31313. PubMed ID: 33324841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
    Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
    J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy against
    Baldwin SL; Reese VA; Larsen SE; Pecor T; Brown BP; Granger B; Podell BK; Fox CB; Reed SG; Coler RN
    Front Microbiol; 2022; 13():935444. PubMed ID: 36090093
    [No Abstract]   [Full Text] [Related]  

  • 5. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
    Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
    Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
    Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
    J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
    Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
    Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
    PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    Choi YH; Kang YA; Park KJ; Choi JC; Cho KG; Ko DY; Ahn JH; Lee B; Ahn E; Woo YJ; Jung K; Kim NY; Reese VA; Larsen SE; Baldwin SL; Reed SG; Coler RN; Lee H; Cho SN
    Infect Dis Ther; 2023 Jun; 12(6):1605-1624. PubMed ID: 37166567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
    Coler RN; Day TA; Ellis R; Piazza FM; Beckmann AM; Vergara J; Rolf T; Lu L; Alter G; Hokey D; Jayashankar L; Walker R; Snowden MA; Evans T; Ginsberg A; Reed SG;
    NPJ Vaccines; 2018; 3():34. PubMed ID: 30210819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.
    Dutill TS; Archer MC; McCollum J; Press C; McNeill L; Hawkins L; Phan T; Laursen E; Cabullos R; Bouchard L; Castro RJ; Lin MW; Roco J; Blois C; Adeagbo B; Guderian JA; Gerhardt A; Beckmann AM; Trappler EH; Kramer RM; Fox CB
    Front Drug Deliv; 2022; 2():. PubMed ID: 37771324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.
    Bertholet S; Ireton GC; Ordway DJ; Windish HP; Pine SO; Kahn M; Phan T; Orme IM; Vedvick TS; Baldwin SL; Coler RN; Reed SG
    Sci Transl Med; 2010 Oct; 2(53):53ra74. PubMed ID: 20944089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
    Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
    J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis.
    Al-Attiyah R; Mustafa AS; Abal AT; El-Shamy AS; Dalemans W; Skeiky YA
    Clin Exp Immunol; 2004 Oct; 138(1):139-44. PubMed ID: 15373916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
    Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
    Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine.
    Archer MC; McCollum J; Press C; Dutill TS; Liang H; Fedor D; Kapilow-Cohen L; Gerhardt A; Phan T; Trappler EH; Orr MT; Kramer RM; Fox CB
    Heliyon; 2023 Jun; 9(6):e17325. PubMed ID: 37366520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.